/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of.
Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA.
Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5.
3D Printed Drugs Market is Likely to Reach Worth of US$ 307.54 Mn in 2022 and Hit Revenue of US$ 742.88 Mn by 2032 at a CAGR of 9.2% from 2022-32 &ndas